INTRODUCTION
Dendritic cells are unique antigenpresenting immune cells that play an important role in regulating the host immune responses (1, 2) . Immature dendritic cells have a unique capability of sensing the maturation signals of infection or inflammation and inducing primary immune responses (3) . These cells can internalize and process bacterial, fungal, viral, and other particulate antigens for major histocompatibility complex (MHC) classes I and II antigen presentation to T cells. Following an encounter with an antigen, dendritic cells mature into antigen-presenting cells, up-regulate their chemokine and co-stimulatory receptors, and migrate to secondary lymphoid organs where they can prime naive T cells and naive and memory B cells and activate natural killer cells to induce specific immune responses (4) (5) (6) . Because of these unique characteristics, dendritic cells have gained considerable interest in the field of vaccine development and immunotherapy. Ex vivo activation and maturation of dendritic cells have been achieved by incubating the cells with viable (7-11) or killed infectious agents or tumor cells and derived antigens (11, 12) . It has been noted that genetic transfection is a highly effective means for induction of immature dendritic cells with sustained immunomodulatory activity (13,14). However, transfection of dendritic cells with plasmid DNA using nonviral reagents has been very difficult, with efficiencies varying from less than 1% to 20% (15-17). Adenoviral-mediated transfection, on the other hand, is successful but requires a fairly high multiplicity of infection (100-1000) (18, 19) , and the utility of this approach is limited by the finding that cellular immune responses are elicited against viral proteins as well (20, 21) , resulting in mild activation of the phenotype of dendritic cells (22) (23) (24) . Here we describe an improved transfection protocol, using the nonviral nonliposomal lipid polymer, TransIT-TKO ® transfection reagent (Mirus, Madison, WI, USA), for transfecting murine dendritic cells with the gene that encodes Coccidioides immitis antigen 2 (Ag2). Experimental studies in a murine model have established that C. immitis Ag2 DNA, a cell wall glycoprotein, induces protective immunity against lethal challenge (25) .
MATERIALS AND METHODS
In the present study, murine dendritic cells ( Valencia, CA, USA). The JAWS II cells were maintained in complete α-minimum essential medium containing ribonucleosides and deoxyribonucleosides (Sigma, St. Louis, MO, USA), 20% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 4 mM L-glutamine, 5 ng/mL recombinant mouse granulocyte macrophage colony-stimulating factor (GM-CSF) (Peprotech, Rocky Hill, NJ, USA), penicillin-streptomycin (100 µg/mL penicillin and 100 U/mL streptomycin; Invitrogen), and 50 µg/mL gentamycin (Invitrogen). The cells were allowed to grow overnight to 50%-60% monolayer confluency in 24-well plates. The cells were washed with serum-free Dulbecco's minimum essential medium (DMEM; Invitrogen) before transfection. The transfection reagent/DNA complex (4 µL:2 µg each plasmid DNA) was prepared in serum-free DMEM by adding plasmid DNAs (2 µg pHYG-EGFP and 2 µg pVR1012-C. immitis Ag2 plasmid DNA) to the TransIT-TKO reagent (in 150 µL DMEM). The mixture was kept at room temperature for at least 5 min before adding it to the cells. The cells were incubated at 37°C in a 5% CO 2 incubator. After a 4-h incubation, an additional 250 µL of complete medium were added. The percent transfection efficiency was evaluated by visual enumeration of the green fluorescencetransfected cells versus the total number of cells using a fluorescent microscope with the appropriate filter (Olympus Optical Co. Ltd., Tokyo, Japan). After a 24-h transfection, both the transfected and nontransfected JAWS II cells were stained with propidium iodide to confirm the viability.
The expression of the C. immitis Ag2 protein was detected by dot-blot immunoblotting. Briefly, the cells were washed once with Dulbecco's phosphate-buffered saline (Invitrogen), and the cell lysates were prepared in homogenization buffer containing 1% Igepal CA-630, 0.1% sodium dodecyl sulfate, protease inhibitors (1.1 µM leupeptin, 1 µM pepstatin, and 0.2 mM phenylmethylsulfonyl fluoride), and 1 mM EDTA (all from Sigma). Various amounts of cell lysate protein were loaded on prewetted nitrocellulose paper (Schleicher & Schuell, Keene, NH, USA) in Tris-buffered saline (TBS; 20 mM Tris-HCl, pH 7.5, 150 mM NaCl). The nonspecific sites were blocked by incubating with 5% bovine serum albumin in TBST (TBS containing 0.05% Tween ® 20). The nitrocellulose sheet was then incubated with goat anti-Ag2 antibody (1:1000) followed by incubation with secondary alkaline phosphatase-labeled rabbit anti-goat immunoglobulin G (IgG) antibody (1: 10,000; Sigma). The immunocomplex was detected by an AP Conjugate Substrate kit (Bio-Rad Laboratories, Hercules, CA, USA).
We also confirmed the phenotype and stimulatory capacity of the pVR1012-C. immitis Ag2 plasmid DNA-transfected JAWS II cells. The cells were transfected with pVR1012 or pVR1012-C. immitis Ag2 plasmid DNA according to the method described here using TransIT-TKO reagent. After a 24-h transfection, cells were incubated with Escherichia coli O111:B4 lipopolysaccharide (LPS) (final concentration 100 
RESULTS
The transfection efficiency ranged from 30% to 50% in three separate experiments using different batch products of TransIT-TKO reagent (Figure 1 ). Approximately 70% of the transfected cells remained viable after a 24-h transfection, as compared to 88% of the nontransfected cells (Figure 2) . The pVR1012-C. immitis Ag2 plasmid DNA-transfected JAWS II cells expressed the C. immitis Ag2 protein (Figure 3) .
The JAWS II cells maintained their immature phenotype during transfection, and there was little or no change in expression of cell surface markers in either the pVR1012 vector or the pVR1012-C. immitis Ag2 plasmid DNA-transfected JAWS II cells, as compared to the nontransfected JAWS II cells, except for CD80 and CD86 ( Figure 4A ). However, after LPS treatment, nontransfected and pVR1012-or pVR1012-C. immitis Ag2 plasmid DNA-transfected JAWS II cells showed up-regulation of MHC class II, CD86, CD80, and CD40 ( Figure 4B) , and cytokines [tumor necrosis factor α (TNFα), interleukin (IL)-1β, and IL-12; data not shown] secretion.
DISCUSSION
The present results indicate that we can reproducibly obtain improved transfection in dendritic cells using TransIT-TKO nonviral transfection reagent. The transfected JAWS II cells remain viable and functionally active and maintain their immature phenotype. While viral-mediated transfection has limitations of being labor-intensive and its utility for gene therapy has immunogenic and safety concerns, the TransIT-TKO system requires only a brief mixing of the commercially available transfection reagent and plasmid DNA. Moreover, the flexibility of this agent for expressing multiple antigens (GFP and C. 
